CrRNA for visually detecting R882C mutation of DNMT3A gene and application of crRNA
Through the PCR-CRISPR/Cas12a system method, crRNA and amplification primers for DNMT3A R882C mutation were designed, which solved the problems of cumbersome, time-consuming and cost-effective detection in the prior art, and achieved high sensitivity and specific mutation detection. Suitable for rapid and economical clinical sample analysis.
Patent Information
- Application Number
- CN202411272066.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-11
AI Technical Summary
The existing DNMT3A R882C gene mutation detection methods have problems such as cumbersome operation, long detection, low sensitivity, high cost and high complexity, and it is especially difficult to efficiently detect low-frequency mutations.
Using the PCR-CRISPR/Cas12a system method, the crRNA and amplification primers for the DNMT3A gene R882C mutation were designed, and visual detection was achieved through the CRISPR/Cas12 enzyme cleavage reaction, and the wild type and mutant type were distinguished by the naked eye reading fluorescence results, which simplified the operation. and reduce costs.
The DNMT3A R882C mutation detection with high sensitivity, strong specificity, low cost and simple operation is achieved, and 1% of low-abundance mutant samples can be detected, with short reaction time and 100% sensitivity and specificity.
Smart Images

Figure CN118995932A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of molecular biology technology, and more specifically, the present invention relates to a crRNA, a kit and a method for visually detecting the R882C mutation of the DNMT3A gene. Background Art
[0002] Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy that poses a serious threat to human health and is the most common type of adult leukemia in China. DNA methyltransferase 3A (DNMT3A) is located in region 2, band 3 (2q23) of the short arm of human chromosome 2. It is an important gene closely related to epigenetic modification and is responsible for de novo DNA methylation modification. DNMT3A gene mutations have been found in a variety of hematological tumors, especially in acute myeloid leukemia (AML), where they have a high frequency and are associated with poor prognosis. Studies have shown that among adult AML patients, about 20% carry DNMT3A mutations, of which 60% occur at the R882 site, and the R882C mutation is one of the most common mutations. The DNMT3AR882C mutation is an important molecular marker for patient stratification and poor prognosis, helping to identify high-risk patients and thus contributing to the formulation of personalized treatment plans.
[0003] In the current detection of DNMT3A R882C gene mutation, commonly used technologies include Sanger sequencing (FGS), high-throughput sequencing (NGS) and real-time fluorescence quantitative PCR (qPCR). Although Sanger sequencing is the most classic method, it has disadvantages such as cumbersome operation, long detection time, and low sensitivity. Although high-throughput sequencing technology (NGS) has the advantages of high throughput and high precision, it requires expensive instruments and equipment, is complex to operate, and requires a high amount of data for the detection of low-frequency mutations. Although the real-time fluorescence quantitative PCR detection method is widely used, its sensitivity is general, and the quantitative accuracy is highly dependent on the standard curve.
[0004] CRISPR / Cas technology is an adaptive immune system derived from bacteria and archaea that can cut exogenous genes and protect bacteria or archaea from external invasion. It has been widely used in the fields of gene editing and nucleic acid detection. Cas12a (formerly known as Cpf1) is an endonuclease in the CRISPR system that can specifically recognize and cut target DNA sequences under the guidance of CRISPR RNA (crRNA). At the same time, Cas12a has non-specific single-stranded DNA trans-cutting activity. When Cas12a recognizes the target DNA, this enzyme activity is activated, thereby cutting the surrounding non-target single-stranded DNA. This property can be used for signal amplification, making it have significant application value in nucleic acid detection. Based on its signal amplification and single-base resolution capabilities, it has been used in rapid, specific and sensitive nucleic acid detection methods.
[0005] Therefore, there is an urgent need to develop a visual detection method with high specificity, high sensitivity, low cost, simple operation and short detection time to effectively detect the DNMT3AR882C gene mutation. Summary of the invention
[0006] Based on this, the purpose of the present invention is to provide a crRNA, a kit and a method for visually detecting the R882C mutation of the DNMT3A gene. By using the kit including the crRNA to detect the test sample, the wild type of the DNMT3A gene and the R882C mutant of the DNMT3A gene can be visually, highly sensitively and specifically distinguished.
[0007] The technical solutions for achieving the above-mentioned invention objectives include the following.
[0008] In a first aspect of the present invention, a crRNA for visually detecting the R882C mutation of the DNMT3A gene is provided, and the nucleotide sequence of the crRNA is shown in SEQ ID NO:3.
[0009] In a second aspect of the present invention, a kit for visually detecting the R882C mutation of the DNMT3A gene is provided, the kit comprising the above-mentioned crRNA and amplification primers, the amplification primers comprising a forward primer having a sequence as shown in SEQ ID NO:4 and a reverse primer having a sequence as shown in SEQ ID NO:5.
[0010] The third aspect of the present invention provides a method for visually detecting the R882C mutation of the DNMT3A gene, which is detected using the above-mentioned kit, comprising the following steps: using the amplification primers to perform PCR amplification on the genomic DNA of the bone marrow puncture of the sample to be tested, performing CRISPR / Cas12 enzyme digestion reaction on the PCR amplification product, and then reading the fluorescence result with the naked eye.
[0011] In the present invention, based on the PCR-CRISPR / Cas12a system, a crRNA for detecting the R882C mutation of the DNMT3A gene is designed, and a mismatched base is introduced at a specific position on the crRNA. At the same time, the PAM site of TTTV is introduced by introducing the mismatched base in the forward primer of the PCR amplification primer to solve the problem of no PAM region at the target mutation site. Under this concept, the crRNA and PCR amplification primers designed by the present invention are used to detect the bone marrow puncture of the sample to be tested, and the wild type and R882C mutant of the DNMT3A gene can be distinguished with high sensitivity (low-abundance mutant samples with a mutation frequency of 1% can be detected) and high specificity.
[0012] The detection method of the present invention can interpret the result with naked eyes only by means of ultraviolet light, does not need to rely on expensive instruments, has low cost and is simple to operate. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 The results of detecting the wild-type fragment (WT) of DNMT3A gene, the R882C mutant fragment (MT) of DNMT3A gene and nuclease-free water (NTC) by 7 crRNAs in Example 2 of the present invention, wherein A is the fluorescence visualization result; B is a scatter plot quantified according to the fluorescence result data.
[0014] Figure 2 The amplification results of different primer pairs in Example 3 of the present invention are shown.
[0015] Figure 3 This is the sensitivity result of the detection method in Example 4 of the present invention.
[0016] Figure 4 This is the test result of the clinical sample in Example 5 of the present invention. DETAILED DESCRIPTION
[0017] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0018] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0019] The experimental methods in the following examples where specific conditions are not specified are generally carried out under conventional conditions, such as those described in Green and Sambrook et al., Molecular Cloning: A Laboratory Manual (2013), or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.
[0020] CRISPR (clustered regularly interspaced shortpalindromic repeats, CRISPR) / Cas (CRISPR-associated proteins, Cas) is an adaptive immune system in bacteria, which has been widely used in gene editing and nucleic acid detection. CRISPR / Cas12 guides double-stranded DNA to cleave a single RuvC catalytic domain through a guide RNA, wherein Cas12 has a non-specific trans-cleavage activity for single-stranded DNA stimulated by target DNA, and based on its continuous signal amplification and single-base resolution ability, has been used to develop a fast, accurate and sensitive nucleic acid detection method. The present invention is based on the detection method of the PCR-CRISPR / Cas12a system, and the DNMT3A gene R882C mutation is detected by designing crRNA and amplification primers for the DNMT3A gene R882C mutation, which has the characteristics of visualization, low cost, simple operation, high sensitivity (the mutation frequency can be detected as 1% low-abundance mutation), and strong specificity.
[0021] In some embodiments of the present invention, a crRNA for visually detecting the R882C mutation of the DNMT3A gene is disclosed, and the nucleotide sequence of the crRNA is shown in SEQ ID NO:3.
[0022] In other embodiments of the present invention, a kit for visually detecting the R882C mutation of the DNMT3A gene is disclosed, the kit comprising the above-mentioned crRNA, and amplification primers, the amplification primers comprising a forward primer having a sequence as shown in SEQ ID NO:4 and a reverse primer having a sequence as shown in SEQ ID NO:5.
[0023] In some embodiments, the kit further comprises a fluorescent probe, the nucleotide sequence of the fluorescent probe is 5 to 15 random bases, the 5' end of the fluorescent probe is labeled with a fluorescent group, and the 3' end of the fluorescent probe is labeled with a quenching group.
[0024] In some of the embodiments, the fluorescent group is FAM, VIC, HEX, TRT, Cy3, Cy5, ROX, JOE or Texas Red, and the quenching group is TAMRA, DABCYL, MGB, BHQ-1, BHQ-2 or BHQ-3.
[0025] In other embodiments of the present invention, a method for visually detecting the R882C mutation of the DNMT3A gene is disclosed, using the above-mentioned kit, comprising the following steps: using the amplification primers to perform PCR amplification on the genomic DNA of the bone marrow puncture of the sample to be tested, performing CRISPR / Cas12 enzyme digestion reaction on the PCR amplification product, and then reading the fluorescence result with the naked eye.
[0026] In some of the embodiments, the PCR amplification reaction system includes: MasterMix 25 μL, forward primer and reverse primer with a final concentration of 20 pmol to 30 pmol, 5 μL to 20 μL template, and nuclease-free water added to 50 μL.
[0027] In some of the embodiments, the reaction procedure of the PCR amplification is: denaturation at 98°C for 30s; denaturation at 98°C for 10s, annealing at 60°C for 10s, extension at 72°C for 10s, 35 cycles; extension at 72°C for 2min.
[0028] In some of the embodiments, the reaction system of the CRISPR / Cas12 enzyme cleavage reaction includes: 2 μL of NEBuffer, Cas12a with a final concentration of 0.05 μM to 0.2 μM, crRNA with a final concentration of 0.05 μM to 0.2 μM, 15 U to 25 U Recombination RNase inhibitor, 0.25 μM to 1 μM fluorescent probe, 2 μL to 10 μL PCR amplification product, and nuclease-free water added to 20 μL.
[0029] In some of the embodiments, the reaction temperature of the CRISPR / Cas12 enzyme cleavage reaction is 37°C±2°C, and the reaction time is 25min to 35min.
[0030] In some of the embodiments, the naked eye reading of fluorescence results includes the following steps: when the sample to be tested has an obvious fluorescence signal, the sample to be tested has the DNMT3A gene R882C mutation.
[0031] In the following examples, probes and primers were synthesized by Shanghai Jierui Biotechnology Co., Ltd.
[0032] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0033] Example 1 Visualization Detection Method for DNMT3A Gene R882C Mutation
[0034] 1. Design crRNA, PCR amplification primers, and single-stranded DNA fluorescent probe FQ-ssDNA reporter
[0035] According to the design of a sequence complementary to the mutant type with a length of 18 nt at the R882C mutation site of the DNMT3A gene, crRNA was reconstructed, and its sequence is shown in SEQ ID NO: 3 A plasmid (pUC57 T7 crRNA) containing the crRNA transcript fragment was synthesized, and the target crRNA was obtained through in vitro transcription and purification steps.
[0036] Since Cas12 requires a specific PAM region (i.e., Protospacer Adjacent Motif, usually TTTV, V is A, G, C) to recognize the target sequence, the PCR amplification primers were designed by introducing T through primers, and the sequences are shown in Table 1.
[0037] Table 1 Primer sequences
[0038] Forward Primer F CCACTATACTGACGTTTCCAACATGAGC(SEQ ID NO:4) Reverse primer R ATGTCCCTTACACACACGCAA(SEQ ID NO:5)
[0039] The nucleotide sequence of the fluorescent probe is 12 random bases, namely, NNNNNNNNNNNN. The 5' end of the probe is labeled with a fluorescent group FAM, and the 3' end is labeled with a quenching group BHQ-1.
[0040] 2. PCR amplification
[0041] PCR amplification was performed using the genomic DNA of the bone marrow aspirate as a template.
[0042] The 50μL PCR amplification system includes: Q5 High-Fidelity 2X MasterMix 25μL, forward primer and reverse primer with a final concentration of 25pmol, 20μL template and nuclease-free water. PCR amplification program: 98℃ pre-denaturation for 30s; 98℃ denaturation for 10s, 60℃ annealing for 10s, 72℃ extension for 10s, 35 cycles; 72℃ extension for 2min.
[0043] 3. CRISPR fluorescence detection reaction
[0044] Take the PCR amplification product for CRISPR / Cas12 digestion, mix the CRISPR / Cas12 digestion system, centrifuge briefly and incubate immediately at 37°C. After 30 minutes, use a nucleic acid gel imager to record the signal. Observe the fluorescence signal of the sample to be tested with the naked eye. If there is an obvious fluorescence signal, the sample to be tested has the DNMT3A gene R882C mutation.
[0045] Among them, 20μL of CRISPR / Cas12 enzyme digestion system includes: NEBuffer 2.1 (10X) 2μL, final concentration of 2pmol Lba Cas12a (Cpf1), crRNA with a final concentration of 4 pmol, 20 U Recombination RNase inhibitor (RRI), FQ-ssDNA reporter 10 pmol, 5 μL PCR amplification product and nuclease-free water.
[0046] Example 2 Screening of highly specific crRNA
[0047] In order to improve the specificity of crRNA, one mismatched base was artificially introduced at different positions on crRNA. A total of 7 crRNAs were designed, of which crRNA1 was the original crRNA, and crRNA2 to 7 were crRNAs with one mismatched base introduced. The specific sequences are shown in Table 2.
[0048] Table 2 crRNA sequences
[0049]
[0050] Note: The bold base U indicates the mutation site, and the italic bold base indicates the introduction of mismatched bases.
[0051] 1. Synthesis of plasmids containing wild-type fragments of DNMT3A gene and plasmids containing R882C mutant fragments of DNMT3A gene
[0052] The DNMT3A gene sequence was searched according to NCBI to determine the mutation site. A plasmid (pUC57-WT) containing the wild-type (WT) fragment of the DNMT3A gene (SEQ ID NO: 1) and a plasmid (pUC57-MT) containing the R882C mutant (MT) fragment of the DNMT3A gene (SEQ ID NO: 2) were synthesized by Sangon Biotech Co., Ltd. The sequences of the WT and MT gene fragments are as follows:
[0053] SEQ ID NO:1
[0054] GCTGTGTGGTTAGACGGCTTCCGGGCAGCCTGGTCTGGCCAGCACTCACCCTGCCCTCTCTGCCTTTTCTCCCCCAGGGTATTTGGTTTCCCAGTCCACTATACTGACGTCTCCAACATGAGCCGCTTGGCGAGGCAGAGACTGCTGGGCCGGTCATGGAGCGTGCCAGTCATCCGCCACCTCTTCGCTCCGCTGAAGGAGTATTTTGCGTGTGTGTAAGGGACATGGGGGCAAACTGAGGTAGCGACACAAAGTTAAACAAACAAACAAAAAACACAAAACATAATAAAACACCAAGAACATGAGGATGGAGAGAAGTATCAGCACCCAGAAGAGAAAAAGGAATTTAAAACAAAAACCACAGAGGCGGAAATACCGGAGGGCTTTGCCTTGCGAAAAG SEQ ID NO:2 (c.2644C>T)
[0062] GCTGTGTGGTTAGACGGCTTCCGGGCAGCCTGGTCTGGCCAGCACTCACCCTGCCCTCTCTGCCTTTTCTCCCCCAGGGTATTTGGTTTCCCAGTCCACTATACTGACGTCTCCAACATGAGCTGCTTGGCGAGGCAGAGACTGCTGGGCCGGTCATGGAGCGTGCCAGTCATCCGCCACCTCTTCGCTCCGCTGAAGGAGTATTTTGCGTGTGTGTAAGGGACATGGGGGCAAACTGAGGTAGCGACACAAAGTTAAACAAACAAACAAAAAACACAAAACATAATAAAACACCAAGAACATGAGGATGGAGAGAAGTATCAGCACCCAGAAGAGAAAAAGGAATTTAAAACAAAAACCACAGAGGCGGAAATACCGGAGGGCTTTGCCTTGCGAAAAG
[0070] 2. Respectively, use plasmids containing wild-type (WT) fragments of the DNMT3A gene (14 ng (10 11 copies / μL)), plasmids containing the R882C mutation (MT) fragments of the DNMT3A gene (14 ng (10 11copies / μL)) and nuclease-free water (NTC) were used as detection samples (templates), and each crRNA was tested using the method of Example 1 to compare the sensitivity and specificity of different crRNAs.
[0071] When the reaction time is 30 min, the naked eye visualization results of different crRNA reactions are as follows: Figure 1 As shown in A in FIG. 1 , it can be seen from the figure that only when crRNA2 is used, the MT signal is strong (dark color) and the WT signal is weak (light color), which can clearly distinguish MT from WT. The fluorescence result data was quantified using Image J software and plotted into a scatter plot, as shown in FIG. Figure 1 As shown in Figure B, it can be seen from the figure that when using crRNA2, the WT signal is lower than that using crRNA4, crRNA1, crRNA3, and crRNA7, while the MT signal is significantly higher than that of crRNA5 and crRNA6. Figure 1 As a result, the crRNA with the best effect was crRNA2 (SEQ ID NO: 3).
[0072] Example 3 Screening of amplification primers
[0073] In this embodiment, two forward primers F1 and F2 and four reverse primers R1, R2, R3, and R4 are designed, and the two forward primers and the four reverse primers are combined to be F1R1, F1R2, F1R3, F1R4, F2R1, F2R2, F2R3, and F2R4, respectively. The primer sequences are shown in Table 3.
[0074] Table 3 Primer sequences
[0075] Primer No. sequence Forward primer F1 CCACTATACTGACGTTTCCAACATGAGC(SEQ ID NO:4) Forward Primer F2 GTCCACTATACTGACGTTTCCAACAT(SEQ ID NO:12) Reverse primer R1 ATGTCCCTTACACACACGCAA(SEQ ID NO:5) Reverse primer R2 CGCAAAATACTCCTTCAGCGG(SEQ ID NO:13) Reverse primer R3 TTGCCCCCATGTCCCTTACA(SEQ ID NO:14) Reverse primer R4 TCGCTACCTCAGTTTTGCCCC(SEQ ID NO:15)
[0076] Then, 8 pairs of primers were used to perform PCR amplification (using human genomic DNA as a template) according to the reaction system and reaction procedure of Example 1, and agarose gel electrophoresis was used for detection to observe the size and color depth of the target band and whether the amplified band was specific for primer screening.
[0077] The results are as follows Figure 2 As shown, from Figure 2 It can be seen that the amplified bands of the eight primer pairs are all specific, and the F1R1 primer pair with the darkest amplified band color (largest product amount) and the shortest amplified fragment was selected as the amplification primer pair.
[0078] Example 4 Sensitivity of the Visual Detection Method of the DNMT3A Gene R882C Mutation of the Present Invention
[0079] The linearized plasmid sample containing the R882C mutant fragment of the DNMT3A gene was diluted to 10 5copies / μL, 10 4 copies / μL, 10 3 copies / μL, 10 2 In addition, the linearized plasmid containing the R882C mutant fragment of the DNMT3A gene was mixed with wild-type human genomic DNA (30 ng / μL, without DNMT3AR882C, used to simulate clinical samples) to prepare samples with mutation frequencies of 100%, 50%, 10%, 1%, 0.1%, and 0% (i.e., all wild-type human genomes).
[0080] 20 μL of the above samples were taken as templates, and amplification was performed according to the PCR reaction system and reaction procedure of Example 1. After amplification, 5 μL of the amplified product was added to the CRISPR / Cas12 enzyme digestion system (same as Example 1) for CRISPR / Cas12 enzyme digestion reaction. The fluorescence was read using a gel imager, and the results were observed with the naked eye. Figure 3 As shown, the results show that when the method of the present invention is used to detect the DNMT3AR882C mutation, 100 copies / μL of sample can be detected when the reaction time is 30 min ( Figure 3 A in the figure), and can detect low-abundance mutant samples with a mutation frequency of 1% ( Figure 3 B).
[0081] Example 5: Using the detection method of the present invention to detect clinical samples
[0082] In this example, bone marrow aspirates of 6 AML patients (whose bone marrow aspirates tested positive for the DNMT3A gene R882C mutation) and 4 people without DNMT3AR882C (whose bone marrow aspirates tested negative for the DNMT3A gene R882C mutation) from Yantai Yuhuangding Hospital were selected (all samples were verified by second-generation sequencing, and the results of the second-generation sequencing are shown in Table 4), genomic DNA was extracted from each of them, and after the concentration was detected, 300 ng of genomic DNA was used as a template, and the detection was performed according to the method of Example 1. The detection results were read using a gel imager, and the results are shown in Table 4. Figure 4 shown.
[0083] Table 4 Results of the second generation sequencing of clinical samples
[0084] serial number Mutation rate (next generation sequencing) serial number Mutation rate (next generation sequencing) C1 2.40% C6 31.00% C2 14.40% C7 0 C3 16.50% C8 0 C4 26.60% C9 0 C5 28.00% C10 0
[0085] Figure 4The results showed that when the reaction time was 30 min, 6 positive samples (C1-C6) produced obvious fluorescence signals after CRISPR / Cas12 digestion, and 4 negative samples (C6-C10) did not produce obvious fluorescence signals after CRISPR / Cas12 digestion. The visualization detection results were consistent with the second-generation sequencing results (Table 3). Clinical sample validation for the DNMT3AR882C target showed that the specificity and sensitivity of the detection method of the present invention were both 100%.
[0086] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0087] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A crRNA for visual detection of DNMT3A gene R882C mutation, characterized in that: The nucleotide sequence of the crRNA is shown in SEQ ID NO:
3.
2. A kit for visually detecting the R882C mutation of the DNMT3A gene, characterized in that: The kit comprises the crRNA according to claim 1, an amplification primer and a fluorescent probe, wherein the amplification primer comprises a forward primer having a sequence as shown in SEQ ID NO: 4 and a reverse primer having a sequence as shown in SEQ ID NO:
5.
3. The kit for visually detecting the R882C mutation of the DNMT3A gene according to claim 2, characterized in that: The nucleotide sequence of the fluorescent probe is 5 to 15 random bases, the 5' end of the fluorescent probe is marked with a fluorescent group, and the 3' end of the fluorescent probe is marked with a quenching group.
4. The kit for visually detecting the R882C mutation of the DNMT3A gene according to claim 3, characterized in that: The fluorescent group is FAM, VIC, HEX, TRT, Cy3, Cy5, ROX, JOE or Texas Red, and the quenching group is TAMRA, DABCYL, MGB, BHQ-1, BHQ-2 or BHQ-3.
5. A method for visually detecting the R882C mutation of the DNMT3A gene, characterized in that: Using the kit according to any one of claims 2 to 4 comprises the following steps: using the amplification primers to perform PCR amplification on the genomic DNA of the bone marrow aspirate of the sample to be tested, performing CRISPR / Cas12 enzyme digestion reaction on the PCR amplification product, and then reading the fluorescence result with the naked eye.
6. The method for visually detecting the R882C mutation of the DNMT3A gene according to claim 5, characterized in that: The PCR amplification reaction system includes: Master Mix 25 μL, forward primer and reverse primer with final concentration of 20 pmol to 30 pmol, 5 μL to 20 μL template, and nuclease-free water added to 50 μL.
7. The method for visually detecting the R882C mutation of the DNMT3A gene according to claim 5, characterized in that: The reaction procedure of the PCR amplification was as follows: denaturation at 98°C for 30s; denaturation at 98°C for 10s, annealing at 60°C for 10s, extension at 72°C for 10s, 35 cycles; and extension at 72°C for 2min.
8. The method for visually detecting the R882C mutation of the DNMT3A gene according to claim 5, characterized in that: The reaction system of the CRISPR / Cas12 enzyme cleavage reaction includes: 2 μL of NEBuffer, Cas12a with a final concentration of 0.05 μM to 0.2 μM, crRNA with a final concentration of 0.05 μM to 0.2 μM, 15U to 25U Recombination RNase inhibitor, 0.25 μM to 1 μM fluorescent probe, 2 μL to 10 μL PCR amplification product, and nuclease-free water added to 20 μL.
9. The method for visually detecting the R882C mutation of the DNMT3A gene according to claim 5, characterized in that: The reaction temperature of the CRISPR / Cas12 enzyme cleavage reaction is 37°C±2°C, and the reaction time is 25min to 35min.
10. The method for visually detecting the R882C mutation of the DNMT3A gene according to any one of claims 5 to 9, characterized in that: The naked eye reading of fluorescence results comprises the following steps: when the sample to be tested has an obvious fluorescence signal, the sample to be tested has the DNMT3A gene R882C mutation.
Citation Information
Patent Citations
Method, primer and kit for detecting DNMT3A mutation site
CN103540659A
Detection kit and detection method for IDH1 or IDH2 gene mutation
CN113136429A
CrRNA, isothermal amplification primer and kit for detecting FLT3-F691L mutation
CN113584167A
CRISPR / Cas12-based composition for detecting Leber hereditary optic neuropathy through one-step method, kit and application
CN117887841A
Targeted genome editing based on CRISPR / Cas9 system using short linearized double-stranded DNA
KR1020160133380A
